Ligand (LGND) Breakout! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout!

LGND 190.43

-0.7%

Feb 6 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Henry Niman who wrote (28219)	2/18/1999 10:37:00 AM
From: J Stone	Read Replies (2) of 32384

Henry, Just to clarify: "Today's press release does indicated that the insulin sensitization aspects of Targretin, identified in mouse models. was confirmed in the European Phase II trials in type II diabetes patients." This means that Targretin was effective in treating diabetes aside from the triglyceride effects, correct? Do we know whether the insulin sensitization aspects were as effective as in mice? (If so, then I view the news as good because the science is confirmed as the "side effects" can be dealt with by more precise compounds: i.e; the second generation compounds. This view will be confirmed if LLY begins a diabetes trial with a new LGND compound in the not too distant future.) TIA Jeff

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next